A laboratory on Long Island has found a breakthrough in the fight against pancreatic cancer that can “intercept” its spread.

Pancreatic cancer is one of the most aggressive cancers and has one of the lowest survival rates—only 10% after five years.

The “Research Spotlight” series is written by Dr. Anna Berkenblit, PanCAN’s Chief Scientific and Medical Officer. Each month, ...

Researchers at City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the U.S.

City of Hope researchers demonstrate proof of concept for a novel targeted therapy for pancreatic cancer, exploiting transcription-replication conflicts to combat treatment resistance.

A review paper published last year in European Journal of Medicinal Chemistry characterized Myc as the “oncogene from ...

Researchers have identified a new molecular target for treating pancreatic cancer. Scientists focused on transcription-replication conflicts (TRCs), which occur when the mechanisms responsible for ...

Reference: Vinaixa J, Martínez-Bosch N, Gibert J, et al. Nuclear Galectin-1 promotes KRAS-dependent activation of pancreatic cancer stellate cells. PNAS. 2025;122(14):e2424051122. doi: ...

A new study focused on transcription-replication conflicts, which occur when mechanisms responsible for gene expression and genome duplication collide.

The "KRAS Inhibitors Market, Drug Sales, Patent, Price & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering. The global market for KRAS inhibitors has seen ...

Nuclear Galectin-1 promotes KRAS-dependent activation of pancreatic cancer stellate cells. Proc Natl Acad Sci U S A. 2025 Apr 8;122(14):e2424051122. doi: 10.1073/pnas.2424051122. Epub 2025 Apr 2.